| 000 | 01782 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513074551.0 | ||
| 264 | 0 | _c19930305 | |
| 008 | 199303s 0 0 eng d | ||
| 022 | _a0272-6386 | ||
| 024 | 7 |
_a10.1016/s0272-6386(12)81093-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBailey, T C | |
| 245 | 0 | 0 |
_aSymptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. _h[electronic resource] |
| 260 |
_bAmerican journal of kidney diseases : the official journal of the National Kidney Foundation _cFeb 1993 |
||
| 300 |
_a196-201 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xtherapeutic use |
| 650 | 0 | 4 | _aCadaver |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xprevention & control |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aKidney Transplantation _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aMuromonab-CD3 _xtherapeutic use |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aPowderly, W G | |
| 700 | 1 | _aStorch, G A | |
| 700 | 1 | _aMiller, S B | |
| 700 | 1 | _aDunkel, J D | |
| 700 | 1 | _aWoodward, R S | |
| 700 | 1 | _aSpitznagel, E | |
| 700 | 1 | _aHanto, D W | |
| 700 | 1 | _aDunagan, W C | |
| 773 | 0 |
_tAmerican journal of kidney diseases : the official journal of the National Kidney Foundation _gvol. 21 _gno. 2 _gp. 196-201 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0272-6386(12)81093-6 _zAvailable from publisher's website |
| 999 |
_c8380850 _d8380850 |
||